Anti-Amyloid Immunotherapy Comparison Matrix for Alzheimer's Disease

Anti-amyloid immunotherapies represent a major therapeutic approach in Alzheimer’s disease, targeting the amyloid-beta (Aβ) protein that is central to the amyloid hypothesis. This comparison matrix provides detailed information on six key immunotherapies: Lecanemab (Leqembi), Donanemab (Kisunla), Aducanumab (Aduhelm), Gantenerumab, Crenezumab, and SAR228810.

Overview Comparison Matrix

flowchart TD
    Aria["Aria"] -->|"associated with"| Cerebral_Amyloid_Angiopathy["Cerebral Amyloid Angiopathy"]
    Amyloid_Beta_Aggregation["Amyloid-Beta Aggregation"] -->|"mediates"| Aria["Aria"]
    style Aria fill:#4fc3f7,stroke:#333,color:#000

Detailed Comparison by Therapy

1. Lecanemab (Leqembi)

Mechanism of Action: Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to Aβ protofibrils (soluble aggregated Aβ) with high affinity. It clears both protofibrils and plaques through Fc-mediated antibody-dependent cellular cytotoxicity (ADCC).

Target: Aβ protofibrils (soluble aggregates) and existing plaques

Phase 3 Trial - CLARITY-AD:

• Patient population: Early AD (MCI due to AD or mild AD dementia) with confirmed amyloid pathology

• Treatment duration: 18 months

• Primary endpoint: Change in CDR-SB: -0.45 vs placebo (27% slowing)

• Secondary endpoints: Amyloid PET SUVr reduction, ADAS-Cog14, ADCOMS

• Key results: Significant reduction in brain amyloid (Centiloids decrease), slowed clinical decline

FDA Status: Full approval (2023); covered by Medicare with evidence requirements

ARIA Incidence:

• ARIA-E (edema): ~12.6%

• ARIA-H (hemorrhage): ~17.3%

• Most cases mild to moderate, manageable with monitoring

Dosing Protocol:

• 10 mg/kg IV infusion every 2 weeks

• Requires MRI monitoring at baseline, then weeks 5, 13, 27, 53

Patient Selection Criteria:

• Early AD (MCI or mild dementia)

• Confirmed amyloid pathology (PET or CSF)

• MMSE score 22-30

• No contraindication to MRI -ApoE4 carrier status affects risk assessment

2. Donanemab (Kisunla)

Mechanism of Action: Donanemab is a monoclonal antibody that targets a specific conformational epitope on Aβ plaques. It binds to Aβ plaques and recruits microglia for plaque clearance through the brain’s innate immune system.

Target: N-terminally truncated Aβ plaques (pyroglutamate-modified Aβ)

Phase 3 Trial - TRAILBLAZER-ALZ 2:

• Patient population: Early symptomatic AD with low/medium tau pathology

• Treatment duration: Up to 76 weeks (with optional treatment suspension)

• Primary endpoint: Change in iADRS: -6.02 vs placebo (35.1% slowing)

• Secondary endpoints: CDR-SB, amyloid PET, tau PET

• Key results: Most robust amyloid removal in class; possible treatment discontinuation after plaque clearance

FDA Status: Full approval (2024)

ARIA Incidence:

• ARIA-E: ~24%

• ARIA-H: ~31%

• Higher than Lecanemab, but most manageable

Dosing Protocol:

• 350 mg infusion every 4 weeks (ramp-up: 3 initial doses at 700 mg then reduce)

• MRI monitoring at baseline, weeks 4, 12, 24, 52, then annually

Patient Selection Criteria:

• Early AD with confirmed amyloid

• Tau imaging (low/medium tau optimal benefit)

• Not recommended for rapid progressors

3. Aducanumab (Aduhelm)

Mechanism of Action: Aducanumab is a human IgG1 monoclonal antibody that binds to multiple forms of Aβ, including monomers, oligomers, and plaques. It was designed to engage the immune system to clear amyloid plaques.

Target: Aβ plaques (broad-spectrum)

Phase 3 Trials - EMERGE and ENGAGE:

• Mixed results; EMERGE showed positive results at high dose

• Primary endpoint: CDR-SB change (delayed in EMERGE, not significant in ENGAGE at prespecified analysis)

• Key result: Amyloid removal significant but clinical benefit debated

• Re-analysis: Suggested benefit in higher dose arm

FDA Status: Withdrawn from market (2024) - manufacturer discontinued commercial availability

Note: Historic importance in field; raised bar for future approvals

4. Gantenerumab

Mechanism of Action: Gantenerumab is a fully human IgG1 monoclonal antibody that binds with high affinity to Aβ plaques. It engages microglia-mediated clearance but showed limited efficacy in trials.

Target: Aβ plaques

Phase 3 Trials - GRADUATE 1 and 2:

• No significant clinical benefit in primary endpoints

• High rates of ARIA (brain edema and microhemorrhages) -did not meet primary endpoints for cognitive benefit

FDA Status: Not approved; development discontinued

Note: Demonstrated amyloid removal but insufficient efficacy

5. Crenezumab

Mechanism of Action: Crenezumab is a humanized IgG4 monoclonal antibody that preferentially targets Aβ oligomers and protofibrils. The IgG4 isotype reduces Fc-mediated effector functions, theoretically reducing ARIA risk.

Target: Aβ oligomers (soluble aggregated Aβ)

Phase 3 Trials - CREAD and CREAD2: -did not meet primary endpoints

• No significant delays in clinical decline

• Lower ARIA rates than other antibodies

FDA Status: Not approved; development discontinued

Note: Interesting proof-of-concept for oligomer-targeting

6. SAR228810

Mechanism of Action: SAR228810 is a monoclonal antibody targeting Aβ protofibrils with high specificity. Development focused on early AD prevention.

Target: Aβ protofibrils

Phase 1/2 Trials:

• Completed early-phase trials

• Showed acceptable safety profile

• Limited public data on efficacy

FDA Status: Not approved; development status unclear

Clinical Efficacy Comparison

Safety and Risk Profile Comparison

Patient Selection Criteria Summary

Economic and Access Considerations

Cross-Linking to Related Content

Alzheimer’s Disease

The main Alzheimer’s Disease disease page should reference this comparison matrix for treatment options.

Amyloid Immunotherapy

• Alpha-Synuclein Immunotherapy: For comparison with Parkinson’s immunotherapies

• Tau Immunotherapy: For comparison with tau-targeting approaches

Biomarkers

• Amyloid PET Imaging: For understanding amyloid detection

• p-Tau Biomarkers: For understanding patient selection

Clinical Trials

• Clinical Trials in Alzheimer’s: For trial listings

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways